Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders by advancing an oral therapy designed to help patients with dystonia improve control of their movement by targeting the root cause of the disease. Founded and incubated at Atlas Venture by physicians and scientists with deep expertise in movement disorders, Vima is advancing VIM0423- a potential first-in-class oral therapy- in a Phase 1 clinical trial, with plans to initiate Phase 2 by the fourth quarter of 2025.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/06/25 | $60,000,000 | Series A |
Access Industries Atlas Venture  Canaan Partners | undisclosed |
